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A B S T R A C T
Schistosomiasis endangers the lives of greater than 200 million people every year and is predominantly con-
trolled by a single class chemotherapy, praziquantel (PZQ). Development of PZQ replacement (to combat the
threat of PZQ insensitivity/resistance arising) or combinatorial (to facilitate the killing of PZQ-insensitive ju-
venile schistosomes) chemotherapies would help sustain this control strategy into the future. Here, we re-ca-
tegorise two families of druggable epigenetic targets in Schistosoma mansoni, the histone methyltransferases
(HMTs) and the histone demethylases (HDMs). Amongst these, a S. mansoni Lysine Specific Demethylase 1
(SmLSD1, Smp_150560) homolog was selected for further analyses. Homology modelling of SmLSD1 and in silico
docking of greater than four thousand putative inhibitors identified seven (L1 – L7) showing more favourable
binding to the target pocket of SmLSD1 vs Homo sapiens HsLSD1; six of these seven (L1 – L6) plus three structural
analogues of L7 (L8 – L10) were subsequently screened against schistosomula using the Roboworm anthelmintic
discovery platform. The most active compounds (L10 - pirarubicin > L8 – danunorubicin hydrochloride) were
subsequently tested against juvenile (3 wk old) and mature (7 wk old) schistosome stages and found to impede
motility, suppress egg production and affect tegumental surfaces. When compared to a surrogate human cell line
(HepG2), a moderate window of selectivity was observed for the most active compound L10 (selectivity indices -
11 for schistosomula, 9 for juveniles, 1.5 for adults). Finally, RNA interference of SmLSD1 recapitulated the egg-
laying defect of schistosomes co-cultivated in the presence of L10 and L8. These preliminary results suggest that
SmLSD1 represents an attractive new target for schistosomiasis; identification of more potent and selective
SmLSD1 compounds, however, is essential. Nevertheless, the approaches described herein highlight an inter-
disciplinary strategy for selecting and screening novel/repositioned anti-schistosomals, which can be applied to
any druggable (epigenetic) target encoded by the parasite's genome.
1. Introduction
Until a safe, reliable and efficacious prophylactic vaccine is devel-
oped, human schistosomiasis will continue to be primarily treated by
anthelmintic chemotherapy. Currently, the drug of choice used in
schistosomiasis control throughout endemic or emerging areas is pra-
ziquantel, a pyrazino-isoquinolone compound developed over 40 years
ago as part of Merck's effort in developing a new tranquilizer class
(reviewed in (Cioli and Pica-Mattoccia, 2003)). While praziquantel is
safe, effective, relatively inexpensive to produce and operationally easy
to deliver (Cioli et al., 2014), its inability to kill immature parasites (Wu
et al., 2011) and its unclear mechanism of action (possibly as a G-
protein coupled receptor antagonist (Chan et al., 2017)) raises concerns
over its sustainability in helping to meet the World Health Organisa-
tion's objective of regional schistosomiasis elimination by 2020 and
beyond (WHO, 2012). Added to these concerns is the spectre of prazi-
quantel-insensitive or resistant parasites developing (Cupit and
Cunningham, 2015). Therefore, new praziquantel replacement (if re-
sistance develops) or combinatorial (with activity against immature
parasites) anti-schistosomals are urgently needed for combatting a
disease that currently affects greater than 200 million people annually
(Colley et al., 2014).
Over the past decade, we, and others, have been involved in de-
veloping and applying high-throughput methods for selecting targets or
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compounds integral to early stage schistosome drug discovery projects
(Kuntz et al., 2007; Caffrey et al., 2009; Fitzpatrick et al., 2009b; Peak
et al., 2010; Rojo-Arreola et al., 2014; Mansour et al., 2016; Aguiar
et al., 2017). Our specific efforts have identified (amongst others) ar-
ginase as a suitable schistosome drug target (Fitzpatrick et al., 2009a;
Hai et al., 2014) and diterpenoids as potential, broad-acting anthel-
mintic compounds (Edwards et al., 2015; Crusco et al., 2018). Due to a
growing realisation that schistosome development is regulated by epi-
genetic processes (Geyer and Hoffmann, 2012), we have now specifi-
cally focused on schistosome epigenetic targets as an additional re-
pository for progressing anti-schistosomal efforts (Geyer et al., 2011,
2018a, 2018b; Cosseau et al., 2016; Roquis et al., 2018). Other in-
vestigators have also interrogated epigenetic space (i.e. the processes
responsible for inheritable phenotypes that do not involve genome al-
terations) for schistosome drug discovery with most attention directed
towards the identification and inhibition of histone modifying enzymes
(HMEs) (e.g. (Azzi et al., 2009; Pierce et al., 2011; Pierce et al., 2012;
Marek et al., 2013; Cabezas-Cruz et al., 2014; Carneiro et al., 2014). As
HMEs are critical regulators of developmental fate and disease patho-
genesis in other metazoans (Butler et al., 2012), their selection as
druggable epigenetic targets in early-stage schistosome drug discovery
projects is well justified.
In this study, we reclassified two functionally opposing HME fa-
milies in Schistosoma mansoni, the histone methyltransferases (HMTs)
and histone demethylases (HDMs). Amongst these epigenetic enzymes,
a S. mansoni lysine specific demethylase 1 (SmLSD1, Smp_150560)
homolog was selected for an early stage drug discovery investigation
based on the importance and role of Homo sapiens lysine specific de-
methylase 1 (HsLSD1) in essential biological processes (Maiques-Diaz
and Somervaille, 2016; Ismail et al., 2018). Using SmLSD1 as a model,
we illustrate how bioinformatics, cheminformatics, functional genomics
and robotic whole organism screening can be synergistically applied to
any druggable (epigenetic) target in the S. mansoni genome.
2. Materials and methods
2.1. Ethics statement
All procedures performed on mice (project license PPL 40/3700)
adhered to the United Kingdom Home Office Animals (Scientific
Procedures) Act of 1986 as well as the European Union Animals
Directive 2010/63/EU and were approved by Aberystwyth University's
(AU) Animal Welfare and Ethical Review Body (AWERB).
2.2. Parasite material
A Puerto Rican strain (NMRI) of Schistosoma mansoni was used
throughout the study and passaged between Mus musculus (Tuck
Ordinary; TO) and Biomphalaria glabrata (NMRI albino and pigmented
hybrid (Geyer et al., 2017)) hosts. Cercariae were shed from both B.
glabrata strains by exposure to light in an artificially heated room
(26 °C) for 1 h and used to percutaneously infect M. musculus (180
cercariae/mouse for the generation of 7 wk old adult worms or 4000
cercariae/mouse for the generation of 3 wk old juvenile worms)
(Smithers and Terry, 1965). Cercariae were also used to generate me-
chanically transformed schistosomula (Colley and Wikel, 1974). Adult
(7 wk post infection) and juvenile (3 wk post infection) schistosomes
were obtained from M. musculus by portal vein perfusion (Duvall and
Dewitt, 1967). Schistosomula, juvenile and adult worms were used for
compound screening. Adult worms were also used for RNA interference
(RNAi).
2.3. Identification of histone methyltransferases (HMTs) and histone
demethylases (HDMs)
The identification of S. mansoni HMTs and HDMs was performed
using two methodologies. The first methodology focused on sequence
similarity between the HMTs/HDMs from H. sapiens and S. mansoni.
Here, representative examples of H. sapiens HMTs/HDMs were down-
loaded from Uniprot (UniProt, 2009) and their protein sequences used
as queries for protein BLAST (BLASTp) searches against the predicted
protein database derived from the S. mansoni genome (v 7.0) hosted in
NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and Wormbase-Parasite
(Howe et al., 2017) using default settings. The human HMTs/HDMs
sequences (and their Uniprot access numbers) used were as follows:
Histone-lysine N-methyltransferase EZH2 (Q15910), Histone-lysine N-
methyltransferase 2A (known as MLL1, Q03164), Histone-lysine N-
methyltransferase SETD2 (Q9BYW2), Histone-lysine N-methyl-
transferase SUV39H2 (Q9H5I1), N-lysine methyltransferase SMYD2
(Q9NRG4), Histone-lysine N-methyltransferase, H3 lysine-79 specific
(known as DOT1L, Q8TEK3), Protein arginine N-methyltransferase 1
(Q63009), Histone-arginine methyltransferase CARM1 (Q86X55), Ly-
sine-specific histone demethylase 1A (O60341), Lysine-specific de-
methylase 4A (known as Jmjd2, O75164), JmjC domain-containing
protein 5 (Q8N371) and Bifunctional arginine demethylase and lysyl-
hydroxylase JMJD6 (Q6NYC1). For the BLASTp searches, full-length
and catalytic domain peptide sequences were used as queries against
the S. mansoni genome (v. 7.0). S. mansoni sequences were recognized
as HMTs or HDMs only if they demonstrated high sequence similarity
(an E value of 1e10−5 or lower) to human HMTs/HDMs and were ob-
served (by visual inspection of the BLASTp pairwise alignments) to
contain conservation over the catalytic domain as defined by InterPro
(Finn et al., 2017), Pfam (Punta et al., 2012), PROSITE (Hofmann et al.,
1999) or SMART (Schultz et al., 1998).
To improve the robustness of our searches, a second methodology
was applied based on the retention of conserved catalytic domain re-
sidues responsible for HMT and HDM enzymatic activity. Here, HMT
and HDM domain identifiers were selected within Interpro, Pfam,
PROSITE and SMART (see Supplementary Table 1). Each signature was
used as the query in Wormbase-Parasite BioMart to identify all putative
S. mansoni proteins containing the aforementioned catalytic domains.
The combination of these approaches led to the identification of 27
HMTs (three novel members) and 14 HDMs (three novel members) in S.
mansoni. The HMTs were grouped into 20 Protein Lysine Methyl
Transferases (PKMTs), 1 PR domain containing methyltransferase
(PRDM), 1 DOT1 Like Histone Lysine Methyltransferase (DOT1L) and 5
Protein Arginine Methyl Transferases (PRMTs). The HDMs were
grouped into 3 Lysine Specific Demethylases (LSDs) and 11 Jumonji
domain-containing proteins (JMJDs). The most closely related
Schistosoma haematobium and Schistosoma japonicum homologous se-
quences for these 27 SmHMTs and 14 SmHDMs were also identified by
BLASTp interrogation of WormBase-Parasite. For the BLASTp searches,
full-length protein sequences of each SmHMT and SmHDM were used as
queries against the S. haematobium and S. japonicum predicted protein
datasets. S. haematobium and S. japonicum sequences were recognized as
the most closely related HMT and HDM homologs respectively (Sh/
SjHMTs and Sh/SjHDMs) only if they demonstrated high sequence si-
milarity (an E value of 1e10−50 or lower). Only the top S. haematobium
or S. japonicum hit (as defined by score) was included (Supplementary
Table 2).
2.4. Multiple sequence alignment and phylogenetic analyses
Alignments of the catalytic domain amino acid sequences within the
identified SmHMTs and SmHDMs were performed with MUSCLE
(Multiple Sequence Comparison by Log Expectation) using the default
parameters (Edgar, 2004). The multiple sequence alignments were in-
terrogated to determine regions of conservation using GBLOCKs 0.91b
set to identify smaller block sizes with less strict flanking positions
(Castresana, 2000). For the HMT phylogenetic analysis, four regions
covering a total of 50 amino acids were chosen by the GBLOCKS soft-
ware, whereas the HDM analysis used three regions containing a total
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of 39 amino acids selected by the GBLOCKs software. Phylogenetic trees
were constructed by MEGA7 using the neighbour-joining method based
on the JTT matrix-based model with default settings and 1000 boot-
strap replications (Kumar et al., 2016) and visualised using the Tree Of
Life v1.0 (Ciccarelli et al., 2006).
2.5. SmHMT and SmHDM domain classifications
The amino acid positions of S. mansoni HMT and HDM domains
having InterPro, SMART and Pfam identifiers were extracted from
Wormbase-Parasite. These catalytic domains were defined as follows:
SET, Su(var)3–9, Enhancer-of-zeste and Trithorax domain for the
PKMTs; DOT1, Disruptor of the telomeric silencing 1 for DOT1L; PRMT
core, Protein Arginine (R) Methyltransferase core domain for PRMTs;
AOL, Amine Oxidase-like domain for LSDs; JMJC, Jumonji C domain
and JMJN, Jumonji N domain for the JMJDs. The start and end position
of these domains were confirmed, or modified if needed, according to
the multiple sequence alignments.
The architecture of these proteins was then populated with other N-
terminal and/or C-terminal domains known from the literature to be
associated with the aforementioned catalytic domains. Graphical re-
presentation of these domains within the schistosome HMTs and HDMs
was prepared using Illustrator for Biological Sequences (IBS, (Liu et al.,
2015)).
2.6. Smhmt and Smhdm transcription profiles
Data from the 37,632 element S. mansoni long-oligonucleotide DNA
microarray studies of Fitzpatrick et al. (2009b) were interrogated to
find the expression profile of the 27 Smhmts and 14 Smhdms across 14
different lifecycle stages. Here, Log2 normalised gene expression data
were subjected to hierarchical agglomerative clustering (Euclidean
distance and complete linkage) using the R statistical programming
language and the Bioconductor package gplots (Gentleman et al.,
2004). The analysed data were then illustrated as a heat map. Raw and
normalised fluorescent intensity values are available via Array Express
under the experimental accession number E-MEXP-2094. Oligonucleo-
tide probes corresponding to each Smhmt and Smhdm as well as their
corresponding log2 expression values are found in Supplementary
Table 2.
2.7. Homology modelling
The homology model of Smp_150560 (S. mansoni Lysine Specific
Demethylase 1, SmLSD1) was prepared with the Molecular Operating
Environment (MOE) 2015.10 (Chemical Computing Group, 2018)
homology tool using a single template approach. The template selected
for SmLSD1 was the three-dimensional structure of H. sapiens LSD1
(HsLSD1; Protein Data Bank – PDB - (Berman et al., 2000) identification
code 2V1D, chain A) (Forneris et al., 2007). The sequence identity
between SmLSD1 and the human template was 41% with a sequence
coverage over 60%, hence well within the acceptable range for com-
parative modelling techniques (Baker and Sali, 2001).
An induced fit option was selected to take into account the presence
of the substrate (histone H3) and cofactor (Flavin Adenine
Dinucleotide, FAD). Ten different intermediate models were built and
minimised using Amber94 before refining the final model, which gen-
erates a Cartesian average of the 10 generated intermediates. The final
model was confirmed by I-TASSER (Iterative Threading ASSEmbly
Refinement) (Yang et al., 2015), Robetta (Kim et al., 2004) and SWISS-
MODEL (Waterhouse et al., 2018) with the overall quality of the model
evaluated by RAMPAGE Ramachandran Plot analysis (http://mordred.
bioc.cam.ac.uk/∼rapper/rampage.php).
2.8. Compound docking to SmLSD1
Compounds capable of binding to SmLSD1 were identified using
Glide docking software within Maestro v10.1 (Maestro, 2015). To in-
itiate docking in either software suite, selection of compounds and
preparation of targets was necessary (Supplementary Fig. 1). Firstly, a
library of commercially available compounds was downloaded from
Specs (www.specs.net, natural compounds and fragment-based library)
in sdf format. These compounds (4,532) were then processed by
Maestro's LigPrep tool to include all the partial charges, the appropriate
protonation state at the defined pH, the proper tautomeric states, the
bond lengths and angles. Secondly, the crystal structure of HsLSD1 was
downloaded from PDB (PDB code 2V1D) and the three-dimensional
structure of SmLSD1 was prepared by homology modelling as described
above. The two structures were processed with the Schrödinger Protein
Preparation Wizard tool using the OPLS_2005 force field to assign
partial charges, bond orders, cap residues, add hydrogen atoms, fill in
missing loops as well as side chains and to minimize the protein
structure relieving any steric clashes. Thirdly, a 12 Å docking grid
(inner-box 10 Å and outer-box 22 Å) was computationally built using,
as a centroid, the structure of the histone H3 that was used for the co-
crystallisation of HsLSD1 as well as for the induced-fit homology
modelling of SmLSD1.
Docking simulations for virtual screening of Specs compounds with
SmLSD1 were next performed in Glide using the standard precision
function (SP; all 4532 compounds) and the results were refined using
the more accurate extra precision (XP) function. In all cases, default
parameters were selected and ten output poses (conformations) per
input ligand were included in the solution. From the 2500 solutions
(conformations) ranked according to the Glide XP scoring function, 500
distinct compounds were identified and retained for HsLSD1 (PDB code
2V1D) docking. The compounds with a more favourable docking score
(XP score) for SmLSD1 compared to HsLSD1 were considered hits and
the top 100 were selected for further processing.
SmLSD1 docking results (Glide XP) of the 100 selected compounds
were saved in a single mol2 file and the docking poses were visually
inspected for their binding mode in MOE. The docking poses of each of
the 100 selected compounds were evaluated according to the ability of
each compound to occupy the target pocket, the number of interactions
between the compound and the target protein, the selection of different
chemical scaffolds and the potential chemical instability or toxicity (i.e.
presence of a nitro group) of the compounds. From this iterative ap-
proach, seven putative SmLSD1 inhibitors (L1-L7) and three structural
L7 analogues (L8 - L10) were identified (Supplementary Table 3).
2.9. Compounds and compound storage
Six of the seven putative SmLSD1 inhibitors (L1-L6) were obtained
from Specs (Supplementary Table 3). As L7 was not commercially
available, three structural analogues (L8 - L10) were purchased from
Sigma Aldrich (UK) (Supplementary Table 3). All compounds were
obtained as powder stocks, solubilised in DMSO to a stock concentra-
tion of 10mM and stored at −20 °C until required. Positive controls for
S. mansoni screens included praziquantel (Sigma-Aldrich, UK) and/or
auranofin (Sigma-Aldrich, UK), which were also diluted in DMSO to a
stock concentration of 10mM and working concentration of 1.6mM.
2.10. Whole organism screening of S. mansoni schistosomula, juveniles and
adults
Mechanically-transformed schistosomula were screened on the
Roboworm platform as previously described (Nur et al., 2017; Crusco
et al., 2018). Primary screens of L1 - L6 and L8 - L10 were performed at
10 μM final concentration (0.625% DMSO); hits (L8 and L10) at this
concentration were subjected to further titration in a secondary screen
(10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.625 μM in 0.625% DMSO).
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Negative (0.625% DMSO) and positive (10 μM auranofin in 0.625%
DMSO) control wells were included in all schistosomula screens. For
primary screens, each putative SmLSD1 inhibitor was tested in dupli-
cate. For secondary screens, each concentration of L8 and L10 was
tested in duplicate and the titration was repeated three times.
Juvenile worm screens (15–20 worms/well) were performed in a 96
well plate format (flat bottom) containing a final volume of 200 μL of
media (DMEM (Gibco, Paisley, UK) supplemented with 10% v/v Hepes
(Sigma-Aldrich, Gillingham, UK), 10% v/v Foetal Bovine Serum (Gibco,
Paisley, UK), 0.7% v/v 200mM L-Glutamine (Gibco, Paisley, UK) and
1X v/v penicillin-streptomycin (Fisher Scientific, UK)). To each well, L8
and L10 were added at the following concentrations: 20 μM, 15 μM,
10 μM, 5 μM and 2.5 μM and 1.25 μM (in 1.25% DMSO). Parasites were
cultured at 37 °C in an atmosphere containing 5% CO2 for 72 h at which
time worm motility was scored between 0 and 4: 0=dead,
1=movement of the suckers only and slight contraction of the body,
2=movement at the anterior and posterior regions only, 3= full body
movement but sluggish and 4= normal movement. DMSO (negative
control, 1.25% DMSO) and praziquantel (positive control, 10 μM in
1.25% DMSO) were included in these juvenile worm assays.
Adult worm screens were initiated as described previously (Crusco
et al., 2018). Briefly, schistosome pairs (3 pairs/well in a 48-well mi-
crotiter plates) were co-cultivated with L8 and L10 (two-fold titrations
between 50 μM and 6.25 μM in 1.25% DMSO) for 72 h at 37 °C in a
humidified atmosphere containing 5% CO2. As controls, schistosome
pairs co-cultivated in DMSO (1.25%) and praziquantel (10 μM in 1.25%
DMSO) were included in these assays. After 72 h, motility was scored
according to defined WHO-TDR metrics (Ramirez et al., 2007) and eggs
deposited in wells were enumerated.
2.11. Preparation of S. mansoni worms for scanning electron microscopy
(SEM)
Adult schistosomes were cultivated (as described above) in sub le-
thal concentrations of L10 (12.5 μM) for 72 h. Afterwards, schistosomes
were prepared for SEM as previously described (Crusco et al., 2018).
2.12. HepG2 culture and MTT assay
Overt cytotoxicity of L8 and L10 was assessed on human HepG2
cells as described previously (Crusco et al., 2018). Briefly,
2× 104 cells/well were seeded in black walled 96-well microtiter
plates (Fisher Scientific, Loughborough, UK) and incubated for 24 h at
37 °C in a humidified atmosphere containing 5% CO2. To each well, L8
and L10 was subsequently added to obtain final concentrations (in
1.25% DMSO) of 200 μM, 100 μM, 75 μM, 50 μM, 20 μM, 10 μM and
1 μM; negative (DMSO; 1.25%) and positive (1% v/v Triton X-100)
control wells were also included. Following a further incubation for
24 h, the MTT assay was performed as previously described (Crusco
et al., 2018; Nur et al., 2017). Dose response curves to calculate CC50
values were generated in GraphPad Prism 7.02.
2.13. RNA interference (RNAi)
Following the perfusion of 7-week infected mice, adult worms were
recovered and RNAi performed as previously described (Geyer et al.,
2011). Smlsd1 and non-specific luciferase (Luc) siRNA duplexes were
purchased from Sigma (siRNA sequences defined in Supplementary
Table 4). Briefly, 5 worm pairs were transferred to 4mm electropora-
tion cuvettes containing DMEM (5.4 g/L D-Glucose, Sigma) supple-
mented with 2mM L-glutamine, 10,000 Units/ml penicillin and
10,000 μg/ml streptomycin. siRNA duplexes (5 μg) were subsequently
added and worms were electroporated with a single pulse at 125 V for
20ms using a ECM-830 Square Wave Porator (BTX). Worms were cul-
tured at 37 °C in DMEM (5.4 g/L D-Glucose, Sigma) supplemented with
10% fetal calf serum, 2mM L-glutamine, 10,000 Units/ml penicillin
and 10,000 μg/ml streptomycin in an atmosphere of 5% CO2 with a
70% media exchange performed every 24 h. At 48 h, worms were
processed for quantitative reverse transcription PCR (qRT-PCR); num-
bers of eggs produced at this time point were also quantified. Separate
worms were maintained in continuous culture for up to 168 h, after
which time, deposited eggs were also quantified.
2.14. Quantitative reverse transcription PCR (qRT-PCR)
Following RNAi with siSmlsd1 and siLuc, mixed-sex adult worms
were incubated for a total of 48 h before processing them for RNA
isolation. Briefly, worms were homogenised using a TissueLyser LT
(Qiagen, UK) in TRIzol Reagent (Invitrogen, UK) before isolation of
total RNA using the Direct-zol RNA Kit (Epigentek, UK). cDNA was then
generated, qRT-PCR performed and data analysed as previously de-
scribed (Fitzpatrick et al., 2009b). qRT-PCR primers are defined in
Supplementary Table 4.
2.15. Statistics
All Statistical analyses were conducted using GraphPad Prism 7
software. To determine significant differences amongst more than two
population means, a Kruskal-Wallis ANOVA followed by Dunn's mul-
tiple comparisons test was used. To determine significant differences
amongst two population means, a student's t-test assuming unequal
variance was performed.
3. Results and discussion
3.1. Re-characterisation of S. mansoni histone methyltransferases (HMTs)
and histone demethylases (HDMs)
Recent studies have suggested that components of the schistosome
epigenetic machinery, especially histone modifying enzymes (HMEs),
should be considered as viable next-generation anthelmintic targets
(Pierce et al., 2012; Cabezas-Cruz et al., 2014). The identification and
optimisation of compounds that affect S. mansoni histone acetyl trans-
ferase- (HATs) or histone deacetylase- (HDAC) activities has been the
predominant focus of such investigations to date (Andrews et al., 2012;
Lancelot et al., 2013; Marek et al., 2013; Carneiro et al., 2014; Schiedel
et al., 2015). However, we and others have pursued the biological
characterisation and chemotherapeutic targeting of two other epige-
netic families in S. mansoni, the histone methyltransferases (HMTs) and
the histone demethylases (HDMs) (Mansure et al., 2005; Cosseau et al.,
2016; Anderson et al., 2017; Roquis et al., 2018). The justification for
this approach originates from current clinical interest in developing
inhibitors of the homologous human enzymes for therapeutic use in
treating cancer and other diseases (McAllister et al., 2016; Zahnow
et al., 2016; Hauser et al., 2018). Therefore, identification of selective
schistosome HMT and HDM inhibitors could lead to the development of
therapeutic strategies for disrupting parasite processes (e.g. reproduc-
tion, egg laying) responsible for schistosomiasis pathology and trans-
mission.
The initial step in this process was to first identify all putative S.
mansoni HMT and HDM family members (Fig. 1). As previously re-
viewed (Cheng et al., 2005; Pedersen and Helin, 2010), HMTs are re-
sponsible for adding a methyl group to N-terminal tails of histone (and
other) proteins whereas HDMs remove this post-translational mod-
ification (Fig. 1A). Within the HMT family are two subfamilies; the
Protein Lysine Methyltransferases (PKMTs), which catalyse the me-
thylation of lysine residues and the Protein Arginine Methyltransferases
(PRMTs), which enzymatically modify arginine residues. With the ex-
ception of DOT1 (Disruptor of telomeric silencing, (Singer et al., 1998))
and PRDM (PRDI-BF1 and RIZ homology domain, (Fog et al., 2012))
containing HMTs, the catalytic region of all other PKMTs contain a
well-conserved SET (Su(var)3–9, Enhancer-of-zeste and Trithorax)
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domain (Fig. 1B). In contrast, the enzymatically active region of all
PRMTs is designated as the PRMT core (Fig. 1B).
The use of the SET domain signature (defined by Interpro, Pfam,
PROSITE and SMART databases, Supplementary Table 1) led to the
identification of 20 putative S. mansoni PKMTs in Wormbase parasite
(Fig. 1C, light blue Smps). Reassuringly, these results confirmed pre-
vious analyses of S. mansoni SET-domain containing PKMTs (Cabezas-
Cruz et al., 2014) but also identified two new putative members
(Smp_149380 and Smp_148360, highlighted in red boxes, Fig. 1C). The
identification of these 20 S. mansoni PKMTs was confirmed by a second
approach based on sequence similarities to human SET-domain con-
taining PKMTs. Here, using human PKMT sequences (full length and
catalytic domains) to query the S. mansoni genome, only these 20
SmPKMTs were found (E value≤ 1e10−5).
Our sequence similarity searches also identified a PRDM-containing
PKMT (Smp_016750, Fig. 1C, dark blue Smp outlined in red box). The
PRDM family is related to SET domain-containing PKMTs, but with
some noticeable differences (reviewed in (Hohenauer and Moore,
2012)). While the catalytic domain of this protein family has 20–30%
sequence similarity to the SET domain, PRDM members also contain a
variety of different amino acid motifs that differentiate them from other
PKMTs (Hohenauer and Moore, 2012). Previously, it was suggested that
S. mansoni contains 6 PRDMs (Vervoort et al., 2016). However, only one
of these proteins (Smp_016750, red box surrounding dark blue ID in
Fig. 1C) fitted the criteria used in this study (a divergent SET domain
along with other motifs including F/Y/IGP/V and ExNL) (Hohenauer
and Moore, 2012). Whether this protein is a catalytically active PKMT is
currently unknown.
In addition to the 20 SET-domain and one PRDM-domain containing
PKMTs, the complementary approaches used in this study confirmed
the presence of only one DOT1L (Smp_165000, dark orange) PKMT and
5 PRMTs (Smp_070340, 029240, 025550, 171150 and 337860, light
orange) (Fig. 1C) (Cabezas-Cruz et al., 2014). A detailed architectural
analysis of each HMT family member was conducted and demonstrated
a rich collection of functional domains important for translating histone
methylation into functional cellular phenotypes (Supplementary
Fig. 2).
Similar to HMTs, HDMs are usually grouped into two distinct sub-
families based on their proposed mechanisms of action: the Lysine
Specific Demethylases (LSDs), which are FAD-dependent amine oxi-
dases and the Jumonji C domain-containing demethylases (JMJDs),
which are Fe(II) and 2-oxoglutarate-dependent enzymes. For identifi-
cation purposes, the catalytic domain signatures of these two sub-
families are the Amine Oxidase-Like (AOL) domain (LSDs) and the
Jumonji C terminal domain (JmjC, usually associated with another
domain known as Jumonji N terminal - JmjN) (Fig. 1B and
Supplementary Table 1). In the case of schistosome LSDs, BLASTp
searches in NCBI using the full protein sequence of the human Lysine-
specific histone demethylase 1A (O60341) and Lysine-specific histone
demethylase 1B (Q8NB78) led to the confirmation of Smp_150560 (E
value= 2e−155) as a putative SmLSD1 and Smp_160810 (E
value= 1e−06) and Smp_162940 (E value=1e−08) as putative
SmLSD2s (Fig. 1B, purple Smps). In support of these findings, the do-
main architecture of these three Smps were further analysed for addi-
tional discriminatory motifs that are characteristic of LSD1 and LSD2
family members (Supplementary Fig. 2). Here, a SWIRM (Swi3p,
Fig. 1. Re-description of Schistosoma
mansoni histone methyltransferases
(HMTs) and histone demethylases
(HDMs).(A) Schematic mode of action re-
presentations for HMT and HDM epigenetic
enzymes on nucleosome histones. HMTs
add a methyl group (Me) onto the N-term-
inal tails of histone proteins, whereas HDMs
remove this chemical modification. (B)
Characteristic domains found within the
HMT (PKMT, DOT1L, PRMT) and HDM
(LSD, JMJD) families. PKMT - Protein
Lysine Methyltransferase, DOT1L -
Disruptor of telomeric silencing 1-like,
PRMT – Protein Arginine Methyltransferase,
LSD - Lysine Specific Demethylase, JMJD -
Jumonji domain-containing protein, SET -
Su(var)3–9, Enhancer-of-zeste and
Trithorax, AOL – amine oxidase-like, JmjN
– Jumonji N terminal, JmjC – Jumonji C
terminal. (C) Phylogenetic tree of S. man-
soni HMTs and HDMs inferred from
Neighbour-joining analysis using MEGA as
described in the Materials and Methods. The
analysis involved 27 HMT and 14 HDM
Smps (Schistosoma mansoni proteins).
Bootstrap support values on the nodes range
from 0 to 25 (highlighted with ), be-
tween 26 and 74 (highlighted with ) and
between 75 and 100 (highlighted with ).
New HMTs and HDMs are highlighted in red
boxes. A colour code was used for each fa-
mily of histone modifying enzymes: light
blue for PKMT - Protein Lysine
Methyltransferases, dark blue for PRDM –
SET domain containing PR methyl-
transferase motifs, dark orange for DOT1L - Disruptor of telomeric silencing 1-like, light orange for PRMT – Protein Arginine Methyltransferases, dark blue for PRDM
– PR Domain containing Methyltransferase, purple for LSD - Lysine Specific Demethylases, green for JMJD - Jumonji domain-containing proteins. (For interpretation
of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Rsc8p, and Moira) domain was found in all three Smps, but a TOWER
domain was only present in Smp_150560. In addition, both
Smp_160810 and Smp_162940 contained two zinc finger (zf-C4H2C2
and zf-CW) domains. Based on these features (Ismail et al., 2018),
Smp_150560 appears to be the only LSD1 present in the S. mansoni
genome.
Regarding the JMJDs, the use of JmjC signatures (Supplementary
Table 1) led to the identification of 11 putative S. mansoni members;
three of these also contain the JmjN domain (Fig. 1C, green Smps and
Supplementary Fig. 2). The most interesting result was the identifica-
tion of three previously unknown JMJDs (Smp_342360, Smp_241580
and Smp_333400; highlighted within red boxes in Fig. 1C and
Supplementary Fig. 2). The domain architecture of these SmHDMs was
analysed in detail (Supplementary Fig. 2) and, similar to the SmHMTs,
illustrated the diversity of motifs used for regulating histone (and other
protein) methylation states.
Using these bioinformatics-led approaches, the putative schistosome
HMTs/HDMs previously identified (Pierce et al., 2012; Cosseau et al.,
2016) were confirmed and an additional six new HMTs/HDMs were
identified. Based on these analyses, the S. mansoni histone methylation
machinery is comprised of 27 HMTs and 14 HDMs. Homologous S.
haematobium and S. japonicum HMTs and HDMs (ShHMT/SjHMT or
ShHDM/SjHDM), when found, were also recorded (Supplementary
Fig. 2).
3.2. Longitudinal transcriptional analysis of S. mansoni HMTs and HDMs
As there has been no comparative gene expression profiling for all
SmHMTs or SmHDMs, transcript abundances of these epigenetic pro-
ducts were inferred from historical DNA microarray data (Fitzpatrick
et al., 2009b) (Fig. 2). When compared to the only previous study ex-
amining gene expression for a single SmHMT family member
(SmPRMT1, Smp_029240), our results are broadly in agreement for
similarly profiled lifecycle stages (adult female and male parasites; fe-
male > male) (Mansure et al., 2005). However, our more extensive
lifecycle analysis of this and all other SmHMTs (Fig. 2A) and SmHDMs
(Fig. 2B) suggests that wide modulation of these family's gene
expression occurs throughout schistosome development. Noticeably, all
members (except the SET domain containing PKMTs Smp_144180,
Smp_160700 and Smp_342100) seem to be expressed in low abundance
in the daughter sporocyst lifecycle stage. Maximal abundance of any
SmHMT or SmHDM was found in the sexually-mature adult lifecycle
stage (5 wk old); here, the three SET domain containing PKMTs
Smp_000700, Smp_078900 and Smp_210650 as well as the two JmjC
containing JMJDs Smp_156290 and Smp_019170 and the AOL-con-
taining LSD Smp_150560 are all found in higher abundance when
compared to other lifecycle stages. In addition to spatial expression
differences and transient variations in SmHMT and SmHDM activities,
these longitudinal gene expression results are likely contributing to the
previously reported developmental changes in schistosome histone
methylation states and are required (together with other post-transla-
tional histone modification) for normal developmental progression in
schistosomes (Roquis et al., 2015, 2018). One SmHDM, the LSD1
homolog Smp_150560 (SmLSD1, Fig. 3), was chosen as a target for
further cheminformatics, functional genomics and whole organism
anthelmintic studies due to the important role of human LSD1 in on-
cogenesis and development (Ismail et al., 2018).
3.3. In silico docking of compounds to SmLSD1
Secondary structural analysis of SmLSD1 predicted a 1164 AA
protein containing a N-terminal SWIRM domain (AAs, 165–287) as well
as a C-terminal amine oxidase like (AOL) domain (AAs, 379–824 and
909–1136) (Fig. 3A). Similar to HsLSD1 (Ismail et al., 2018), the AOL
domain of SmLSD1 is interrupted by a Tower domain (AAs, 825–908).
To progress the cheminformatics selection of putative compounds that
may interfere with SmLSD1 activity, tertiary structural analysis was
next conducted (Fig. 3B). However, as the structure of SmLSD1 is not
currently known, we created a homology model of this schistosome
HDM using chain A of HsLSD1 (PDB entry 2V1D; SmLSD1 and HsHSD1
contain 41% sequence identity over 71% of their entire length), co-
crystallised with AA residues 1–16 of histone 3 (H3; position 4 is a
methylated Lys) and Flavin Adenine Dinucleotide (FAD), as a template.
The SmLSD1 model revealed that the SWIRM domain (orange) adopts a
Fig. 2. S. mansoni hmts and hdms are differentially expressed throughout development.
DNA microarray analysis and heat map representation of (A) hmt and (B) hdm transcript abundance across 14 schistosome lifecycle stages. The expression level for
each hmt or hdm was calculated as the ratio of individual log2 expression values (obtained from (Fitzpatrick et al., 2009b)) to the median hmt or hdm log2 expression
value (red=up-regulated; yellow=down-regulated). Hierarchical clustering (Euclidean distance and complete linkage) of HMT and HDM Smp IDs (rows) are
indicated on both panels. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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six-helical architecture and packs closely to the AOL domain (green).
While the SWIRM domain function is still undefined, it is likely in-
volved in DNA or protein binding (Aravind and Iyer, 2002). The AOL
domain (responsible for SmLSD1 catalytic activity) is folded into two
distinctive subdomains so that the cofactor binding pocket (where FAD
is located, spheres) and the target-binding pocket (where methylated
Lys, yellow stick, of H3 is located) are brought together. The Tower
domain (blue) of SmLSD1 is likely responsible for establishing higher
order protein interactions (Amente et al., 2013). The magnified surface
structure of the target pocket is shown and represents the location
where in silico binding of potential SmLSD1 inhibitors was performed.
The in silico molecular docking of 4532 compounds (representing a
collection of both natural products and small fragment based structures
(Suzuki and Miyata, 2006)) to the SmLSD1 target pocket resulted in the
identification of seven compounds (L1-L7) that had a potential to in-
terfere with the demethylase activity of this schistosome HDM
(Supplementary Fig. 1, Supplementary Table 3). While we could com-
mercially obtain compounds L1-L6, compound L7 was unavailable.
Therefore, prior to conducting whole organism anthelmintic screening
(Fig. 4), we identified and purchased three L7 analogues (L8, L9 and
L10; Supplementary Table 3). These analogues are previously char-
acterised anthracyclines (L8 – daunorubicin hydrochloride, L9 – dox-
orubicin hydrochloride, L10 – pirarubicin) with known antineoplastic
activity (Minotti et al., 2004). All 10 compounds displayed a higher
predicted affinity for the target pocket found in SmLSD1 compared to
HsLSD1 (PDB entry 2V1D) (Supplementary Table 5).
3.4. In vitro screening of putative SmLSD1 interactors
Upon screening of the nine (L1-L6; L8-10) available compounds
against schistosomula on the Roboworm platform (n=2 wells per
compound/120 schistosomula per well; 10 μM single point concentra-
tion), only L8 and L10 affected both parasite phenotype and motility
metrics (Fig. 4A); these two compounds were, thus, considered hits
when compared to positive (auranofin (Kuntz et al., 2007)) and nega-
tive (DMSO) controls. While the central scaffold structures of L8
(daunorubicin hydrochloride) and L10 (pirarubicin) are similar
(Fig. 4B), L10 is a C14-hydroxylated derivative of L8 containing a 4-
tetrahydropyranyl substituent on the amino sugar in the C7 position of
the central scaffold. From this primary screen, L10 appeared to be more
potent than L8 against in vitro cultivated schistosomula (i.e. data points
for L10 are closer to the origin in Fig. 4A). A subsequent dose response
titration of both L10 and L8 confirmed this observation; EC50 values for
both schistosomula motility and phenotype metrics were lower for L10
when compared to L8 (Fig. 5). This anthelmintic trend (L10 > L8) was
also observed for juvenile (3 wk old) schistosomes co-cultivated with
both compounds (Fig. 6). The greater anthelmintic activity of L10 over
L8 may be associated with potential increased membrane permeability
(L10: LogP= 2.06; L8: LogP= 1.83; Supplementary Table 3), struc-
tural differences in its sugar side chain (Supplementary Table 3 and
(Denel-Bobrowska and Marczak, 2017)) or its ability to form an addi-
tional hydrogen bond with Asn653 due to the hydroxylic group in C14
within the target pocket of SmLSD1 (compare highlighted orange cir-
cles; Supplementary Fig. 3). Further medicinal chemistry investigations
Fig. 3. Secondary and tertiary structural
representations of Smp_150560, the clo-
sest S. mansoni ortholog of Homo sapiens
Lysine Specific Demethylase (LSD) 1.(A)
Characteristic LSD1 domains found in
Smp_150560 (1164 AA) include a SWIRM
(orange arrow) domain, an Amine Oxidase-
Like (AOL, green) domain and a tower
(blue) domain. Amino acid length of each
domain is provided. (B) Homology model of
Smp_150560 in complex with the cofactor
FAD and substrate histone H3 protein (20
residues fragment) produced using human
LSD1 (PDB entry 2V1D) as the template.
Domains are indicated and follow the col-
ouring scheme in (A); FAD atoms are re-
presented as spheres, histone H3 (methy-
lated Lys is a yellow stick) is represented by
yellow ribbon. Magnified target pocket
(square) in SmLSD1 is represented as a
surface model showing the histone (with
methylated Lys) located in a channel con-
necting to the flavin adenine dinucleotide
(FAD) cofactor (FAD shown as spheres:
carbon (grey, oxygen (red), nitrogen
(blue)). (For interpretation of the references
to colour in this figure legend, the reader is
referred to the Web version of this article.)
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are necessary to disentangle these (or other) possibilities.
We next explored the effect of both L10 and L8 on adult male and
female schistosome pairs (7 wk old) (Fig. 7). Consistent with the
schistosomula and juvenile worm screens, L10 displayed greater ac-
tivity than L8 on adult worm motility (Fig. 7A; L10 EC50= 14.18 μM,
L8 EC50 > 50 μM). While egg production was also affected by co-cul-
tivation with both compounds, L10 again demonstrated a more striking
effect in inhibiting this critical process involved in host im-
munopathology and lifecycle transmission (Fig. 7B). The higher EC50
recorded for adult parasites (14.18 μM) compared to schistosomula
(1.5 μM for motility - 2.5 μM for phenotype; Table 1), despite greater
Smlsd1 abundance in adults (Fig. 2), suggested that L10 permeability/
efflux could affect the activity of the compound in vitro or SmLSD1
function may differ across the schistosome lifecycle. Nevertheless, in-
cubation of S. mansoni adult worms with the HAT inhibitors PU139,
trichostatin A, valproic acid, sirtinol, salermide and MS3 also led to
worm mortality or egg production defects (Dubois et al., 2009; Lancelot
et al., 2013; Carneiro et al., 2014), further supporting a critical role for
the careful regulation of histone post-translational modifications in
adult (and other lifecycle stages) schistosome biological processes.
As previously indicated, L10 was consistently more potent (com-
pared to L8) in affecting schistosome phenotype or motility, regardless
of lifecycle stage examined. Therefore, SEM analysis of adult male
schistosomes co-cultivated in a sub-EC50 concentration of this com-
pound (12.5 μM) was performed to assess if L10 also affected surface
worm morphology (Fig. 7C). Here, when compared to DMSO treated
Fig. 4. In vitro schistosomula screen of putative
SmLSD1 inhibitors.(A) Mechanically-transformed
schistosomula (n= 120) were incubated with the puta-
tive SmLSD1 inhibitors L1 - L6 and L8 - L10 (10 μM in
0.625% DMSO; each of them in duplicate) for 72 h at
37 °C in a humidified atmosphere containing 5% CO2. At
72 h, the effect that each compound has on parasite
phenotype and motility was assessed by the high
throughput platform Roboworm. The graph shows the
results of the anti-schistosomal activity of the selected
compounds compared to DMSO (0.625%) and Auranofin
(10 μM in 0.625% DMSO), respective negative and posi-
tive controls (average of 24 different replicate wells/
control). Compounds with activity on both schistosomula
phenotype and motility are shown within the ‘Hit Zone’
(delineated by the dotted lines in the graph). Z' scores
(Zhang et al., 1999) for these screens are included on the
graph. (B) Chemical structures of the two compounds (L8
and L10) showing the strongest anti-schistosomula ac-
tivity.
Fig. 5. Dose response titrations of L10
and L8 against schistosomula.
The two hit compounds were screened
against mechanically-transformed schisto-
somula at 10 μM and lower concentrations
(5 μM, 2.5 μM, 1.25 μM and 0.625 μM) as
described in Fig. 4. Three independent dose
response titrations were performed and
each compound concentration was eval-
uated in duplicate. Dose response curves for
S. mansoni schistosomula phenotype and
motility were prepared using GraphPad
Prism (mean ± SD of mean is indicated for
each compound concentration). Estimated
EC50s calculated from these dose response
curves are summarized in the table. Z'
scores (Zhang et al., 1999) for these three
repeat titrations were 0.40 for motility and
0.30 for phenotype.
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control males, incubation of adult males in the presence of L10 led to
the disruption and surface erosion of tegumental membranes. This type
of surface damage has been seen before and is consistent with stress and
an inability to maintain molecular control of this protective barrier
(Edwards et al., 2015; Crusco et al., 2018). While we present molecular
docking support suggesting that L10 interacts with the target pocket of
SmLSD1 (Supplementary Fig. 3) and, thus, affects histone demethylase
activity, it is also possible that L10 (pirarubicin) inhibits DNA and RNA
synthesis, blocks transcription or produces membrane damaging free
oxygen radicals as previously reported (reviewed in (McGowan et al.,
2017)). Indeed, a degree of cytotoxicity was observed for L10 (and L8)
using the surrogate human HepG2 cell line; however, there was a
window of selectivity (i.e. selectivity index – 1.5 to 14) between this
compound's anthelmintic activity and general cytotoxicity (Table 1 and
Supplementary Fig. 4). Anthracycline cytotoxicity and tumour specifi-
city is a recognized phenomenon and represents an area of growing
research in developing more selective antineoplastic compounds
(Edwardson et al., 2015). Nevertheless, a combination of multifactorial
L10-mediated mechanisms of action (in addition to SmLSD1 inhibition)
could be contributing to the anthelmintic stress response (s) observed
(i.e. motility defects, surface damage and egg production inhibition);
further investigations are required to tease apart L10's inhibition of
SmLSD1 versus other biological processes.
3.5. RNAi of Smlsd1 in adult schistosomes
As a first step in progressing this objective, we undertook a func-
tional genomics approach of SmLSD1 inhibition to see if aspects of L10-
associated adult worm phenotypes could be recapitulated (Fig. 8). RNAi
of adult (7 wk old) worm pairs, using Smlsd1 siRNAs, led to a significant
reduction (56%, p=0.001) in transcript abundance after 48 h when
compared to worm pairs treated with siluc siRNAs (Fig. 8A). At this
time-point, egg production was also significantly inhibited (∼50% re-
duced) in siSmlsd1 treated worms (Fig. 8B). While Smlsd1 transcript
reduction (56%) and egg production inhibition (50%) at 48 h is only
correlated, the magnitude by which both processes were affected sug-
gests a role for SmLSD1. After 7 days, siSmlsd1 treated worms recovered
slightly, but were still producing far less eggs than their siluc counter-
parts (Fig. 8B). While this could reflect a sustained egg production
defect carrying over from 48 h, these results equally support a delay in
normal egg production (compare the difference in eggs produced at the
two timepoints between the two siRNA treatments). Perhaps a more
significant difference in egg production (between siSmlsd1 vs siluc
treated worm pairs) would be observed if greater than 56% knockdown
in Smlsd1 was achieved and allow for these two scenarios to be re-
solved. Nevertheless, these functional genomics results, targeting
Smlsd1, support the egg production defects mediated by L10 (Fig. 7B)
and validate the molecular targeting of this S. mansoni HDM for follow-
on investigations.
3.6. Conclusions
Here, we detail a strategy by which interdisciplinary approaches for
pursuing drug discovery (bioinformatics, cheminformatics, whole or-
ganism screening and functional genomics) can be leveraged to identify
next-generation schistosome chemotherapeutic targets. By re-classi-
fying two opposing enzymatic families responsible for histone (and
other protein) methylation and demethylation, we have identified
SmLSD1 (and through homology, ShLSD1 – MS_02208 and SjLSD1 –
Sjp_0082330; Supplementary Table 2) as a druggable candidate. With
the further repositioning of antineoplastic compounds (L8 - daunor-
ubicin and L10 - pirarubicin) as putative SmLSD1 (and potentially
ShLSD1 and SjLSD1) inhibitors, medicinal chemistry optimisation could
lead to the generation of more potent and selective anti-schistosomals
that negatively affect epigenetic processes underlying schistosome de-
velopment and pathogenesis.
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